The North Broward Hospital District’s Baa2 rating and stable outlook on its outstanding bonds have been affirmed by Moody’s Investor Services. According to Moody’s, “the affirmation of the Baa2 expects that the North Broward Hospital District will generate stable, but modest, margins in fiscal 2021,” adding that the system is expected to “maintain a strong cash position to help absorb the impact of COVID-19 and provide robust coverage of a low risk debt burden.”

“Maintaining the designation of ‘stable’ during a global pandemic demonstrates Broward Health’s strong fiscal positioning,” said Alex Fernandez, senior vice president and CFO of Broward Health. “Our leadership team and caregivers have worked tirelessly during this pandemic to perform at the highest level of care with financial integrity and compliance. We look forward to the future and improved financial conditions that should further positively impact our financial outlook.”
 
In the Moody’s report released February 24, 2021, Broward Health was acknowledged for its strong balance sheet and its modest debt load. “The North Broward Hospital District will continue to benefit from the system’s role as a large and diversified health system and as a safety net provider for Broward County.”


Holy Cross Health is one of the first in South Florida to offer a new lung valve treatment for patients with severe COPD/emphysema. 

Recently approved by the FDA under its “Breakthrough Devices” status, the Zephyr® Endobronchial Valve treatment is a major advancement because it is the first minimally invasive procedure to help emphysema sufferers breathe easier without major surgery. Through a simple bronchoscopy, the valves improve a patient’s quality of life by allowing them to breathe easier, reducing the shortness of breath, while promoting a more active and energetic lifestyle. 
 
“We are very excited to have this new treatment option because emphysema patients are often in poor physical condition, struggling with each breath despite medication therapy. Before the Zephyr Valves, the only options for relief were highly invasive treatments including lung surgeries,” said Sam G. Kosseifi, M.D., DABSM, lead pulmonologist at Holy Cross Health. “Being able to offer this minimally invasive procedure has the potential to improve the quality of life for many emphysema sufferers in Florida and beyond.”
 
The one-time procedure is done during a simple bronchoscopy that requires no cutting or incisions. During the procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped. Keeping air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath. 


Bluma Wellness Inc. is pleased to announce that the Company has obtained a final order of the Supreme Court of British Columbia approving the previously announced acquisition of the Company by Cresco Labs Inc., by way of a plan of arrangement under the Business Corporations Act.

If the Arrangement is completed, Cresco will, among other things, acquire all of the issued and outstanding common shares in the capital of the Company, in exchange for which holders of Bluma Shares will receive 0.0859 of a subordinate voting share of Cresco for each Bluma Share held, subject to adjustment in accordance with the terms of the Arrangement.
 
The Arrangement was approved by the Bluma Shareholders at the special meeting of Bluma Shareholders held on March 19, 2021. The completion of the Arrangement remains subject to a number of conditions, including but not limited to the receipt of regulatory approval of the Florida Department of Health Office of Medical Marijuana Use.


Curaleaf Holdings, Inc. announced that Carlos Madrazo has been appointed to the role of Senior Vice President of Investor Relations and Capital Markets for Curaleaf, a new position.

Madrazo will work with Curaleaf’s Executive Leadership Team to help advance the knowledge and understanding of the Company’s strategic positioning within global cannabis and consumer packaged goods markets, the Company’s successful track record for growth and execution, as well as the value creation opportunity for shareholders. Madrazo will also assist in corporate finance and strategic planning matters.
 
Madrazo has over 20 years of experience in investor relations, investment banking and operations at an international level. Most recently, he led Investor Relations and Sustainability for Grupo Televisa, S.A.B. Prior to Televisa, Carlos held positions with Tutv Llc as CFO, where he launched and co-managed a new business venture and with ING Barings, where he led Latin American media and entertainment investment banking. Carlos also spent six years with Chase Securities in its Global Mergers and Acquisitions Group. He holds an MBA from the University of Notre Dame and a Bachelors of Arts degree in Economics.


Bluma Wellness Inc. is pleased to announce that the Company has obtained a final order of the Supreme Court of British Columbia approving the previously announced acquisition of the Company by Cresco Labs Inc., by way of a plan of arrangement under the Business Corporations Act.

If the Arrangement is completed, Cresco will, among other things, acquire all of the issued and outstanding common shares in the capital of the Company, in exchange for which holders of Bluma Shares will receive 0.0859 of a subordinate voting share of Cresco for each Bluma Share held, subject to adjustment in accordance with the terms of the Arrangement.
 
The Arrangement was approved by the Bluma Shareholders at the special meeting of Bluma Shareholders held on March 19, 2021. The completion of the Arrangement remains subject to a number of conditions, including but not limited to the receipt of regulatory approval of the Florida Department of Health Office of Medical Marijuana Use.